Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Liver Cirrhosis

  Free Subscription

Articles published in J Gastroenterol Hepatol

Retrieve available abstracts of 158 articles:
HTML format

Single Articles

    July 2021
  1. ATTEBERRY P, Biederman B, Jesudian A, Lucero C, et al
    Mortality, Sepsis, and Organ Failure in Hospitalized Patients with Cirrhosis Vary by Type of Infection.
    J Gastroenterol Hepatol. 2021 Jul 22. doi: 10.1111/jgh.15633.
    PubMed     Abstract available

  2. KRIGE J, Jonas E, Spence R, Bernon M, et al
    Letter to the editor: The complexities of predicting outcome in cirrhotic patients with acute variceal bleeding.
    J Gastroenterol Hepatol. 2021 Jul 12. doi: 10.1111/jgh.15622.

  3. ITO T, Hanafusa N, Soneda N, Isoai A, et al
    Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) against cirrhotic ascites in comparison with malignancy-related ascites.
    J Gastroenterol Hepatol. 2021 Jul 11. doi: 10.1111/jgh.15620.
    PubMed     Abstract available

    June 2021
  4. ZULLO A, Soncini M, Bucci C, Marmo R, et al
    Clinical outcomes in cirrhotics with variceal or nonvariceal gastrointestinal bleeding: a prospective, multicenter cohort study.
    J Gastroenterol Hepatol. 2021 Jun 29. doi: 10.1111/jgh.15601.
    PubMed     Abstract available

    May 2021
  5. YANG C, Liu J, Shi Q, Huang S, et al
    Effect of splenectomy on the outcomes in patients with cirrhosis receiving transjugular intrahepatic portosystemic shunt.
    J Gastroenterol Hepatol. 2021 May 11. doi: 10.1111/jgh.15543.
    PubMed     Abstract available

  6. HSU WF, Tsai PC, Chen CY, Tseng KC, et al
    Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (T-COACH).
    J Gastroenterol Hepatol. 2021 May 7. doi: 10.1111/jgh.15538.
    PubMed     Abstract available

    March 2021
  7. SHARMA C, Cococcia S, Ellis N, Parkes J, et al
    Systematic review: Accuracy of The Enhanced Liver Fibrosis Test for diagnosing advanced liver fibrosis and cirrhosis.
    J Gastroenterol Hepatol. 2021 Mar 5. doi: 10.1111/jgh.15482.
    PubMed     Abstract available

    February 2021
  8. WEST J, Gow PJ, Testro A, Chapman B, et al
    Exercise physiology in cirrhosis and the potential benefits of exercise interventions - a review.
    J Gastroenterol Hepatol. 2021 Feb 27. doi: 10.1111/jgh.15474.
    PubMed     Abstract available

  9. KIM JH, Park SW, Jung JH, Park DH, et al
    Bedside Risk-Scoring Model for Predicting 6-Week Mortality in Cirrhotic Patients Undergoing Endoscopic Band Ligation for Acute Variceal Bleeding.
    J Gastroenterol Hepatol. 2021 Feb 4. doi: 10.1111/jgh.15426.
    PubMed     Abstract available

    January 2021
  10. YI F, Guo X, Wang L, Xu X, et al
    Spontaneous splenorenal shunt may decrease the long-term survival of liver cirrhosis by compromising liver volume.
    J Gastroenterol Hepatol. 2021 Jan 3. doi: 10.1111/jgh.15386.
    PubMed     Abstract available

  11. LUM JHM, Cheah MCC, Leow WQ, Wan WK, et al
    Clinical profile of non-alcoholic fatty liver disease in nonobese patients.
    J Gastroenterol Hepatol. 2021;36:257-261.
    PubMed     Abstract available

  12. TAKEMURA K, Takizawa E, Tamori A, Nakamae M, et al
    Association of serum autotaxin levels with liver fibrosis in patients pretreatment and posttreatment with chronic hepatitis C.
    J Gastroenterol Hepatol. 2021;36:217-224.
    PubMed     Abstract available

    December 2020
  13. TERRA C, Perez R
    Albumin for cirrhotic patients with infections unrelated to spontaneous bacterial peritonitis: A still no answered question.
    J Gastroenterol Hepatol. 2020;35:2290-2291.

    September 2020
  14. SANDI BB, Leao GS, de Mattos AA, de Mattos AZ, et al
    Long-term albumin administration in patients with cirrhosis and ascites: a meta-analysis of randomized controlled trials.
    J Gastroenterol Hepatol. 2020 Sep 10. doi: 10.1111/jgh.15253.
    PubMed     Abstract available

  15. KOGISO T, Hashimoto E
    Are low triglyceride levels the cause or an outcome of advanced liver fibrosis in elderly patients with nonalcoholic fatty liver disease?
    J Gastroenterol Hepatol. 2020;35:1459-1460.

  16. CHEN TP, Lai M, Lin WY, Huang KC, et al
    Metabolic profiles and fibrosis of nonalcoholic fatty liver disease in the elderly: A community-based study.
    J Gastroenterol Hepatol. 2020;35:1636-1643.
    PubMed     Abstract available

  17. YIP TC, Lee HW, Wong VW, Wong GL, et al
    Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B.
    J Gastroenterol Hepatol. 2020;35:1610-1618.
    PubMed     Abstract available

  18. POUSTCHI H, Majd Jabbari S, Merat S, Sharifi AH, et al
    The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment.
    J Gastroenterol Hepatol. 2020;35:1590-1594.
    PubMed     Abstract available

    July 2020
  19. ZAREBSKA-MICHALUK D, Jaroszewicz J, Buczynska I, Simon K, et al
    Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.
    J Gastroenterol Hepatol. 2020;35:1238-1246.
    PubMed     Abstract available

  20. FAN J, Wang Q, Luo B, Chen H, et al
    Prevalence of prothrombotic factors in patients with Budd-Chiari syndrome or non-cirrhotic nonmalignant portal vein thrombosis: A hospital-based observational study.
    J Gastroenterol Hepatol. 2020;35:1215-1222.
    PubMed     Abstract available

    June 2020
  21. BRAHMANIA M, Wiskar K, Walley KR, Celi LA, et al
    Lower household income is associated with an increased risk of hospital readmission in patients with decompensated cirrhosis.
    J Gastroenterol Hepatol. 2020 Jun 20. doi: 10.1111/jgh.15153.
    PubMed     Abstract available

  22. CAO DB, Wang YS
    Gastrointestinal: Intrahepatic periportal masses with uncommon computed tomography patterns: Hepatic extramedullary hematopoiesis of primary mylofibrosis.
    J Gastroenterol Hepatol. 2020 Jun 7. doi: 10.1111/jgh.15069.

  23. LEE HW, Ahn SH
    How do genetic variants affect our interpretation of non-invasive tests for non-alcoholic fatty liver disease?
    J Gastroenterol Hepatol. 2020;35:915-916.

  24. SHIN SK, Kim KO, Kim SH, Kwon OS, et al
    Exogenous 8-hydroxydeoxyguanosine ameliorates liver fibrosis through the inhibition of Rac1-NADPH oxidase signaling.
    J Gastroenterol Hepatol. 2020;35:1078-1087.
    PubMed     Abstract available

  25. NGUYEN TH, Wardell R, Chitturi S, Teoh N, et al
    When the liver gets stiff, the tough get moving.
    J Gastroenterol Hepatol. 2020;35:953-959.
    PubMed     Abstract available

  26. CHEN H, He C, Lv Y, Fan J, et al
    Long-term results of variceal bleeding management in 302 patients with chronic extrahepatic portal vein obstruction.
    J Gastroenterol Hepatol. 2020;35:1049-1056.
    PubMed     Abstract available

    March 2020
  27. KIM JH, Kang SH, Lee M, Choi HS, et al
    Improved Detection of Hepatocellular Carcinoma by Dynamic CT in Cirrhotic Patients With Chronic Hepatitis B: A Multi-Center Study.
    J Gastroenterol Hepatol. 2020 Mar 28. doi: 10.1111/jgh.15046.
    PubMed     Abstract available

  28. YE L, Yu Y, Zhao Y
    Icariin-induced miR-875-5p attenuates epithelial-mesenchymal transition by targeting hedgehog signaling in liver fibrosis.
    J Gastroenterol Hepatol. 2020;35:482-491.
    PubMed     Abstract available

  29. JANG TY, Huang CI, Yeh ML, Liang PC, et al
    Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents.
    J Gastroenterol Hepatol. 2020;35:473-481.
    PubMed     Abstract available

    February 2020
  30. DA SILVA FRANCO KMV, Vieira WB, Dias ARN, Falcao ASC, et al
    Doppler ultrasonography: A non-invasive method used to diagnose and follow up patients with chronic hepatitis C.
    J Gastroenterol Hepatol. 2020;35:314-319.
    PubMed     Abstract available

    January 2020
  31. PATERNOSTRO R, Kapzan L, Mandorfer M, Schwarzer R, et al
    Anemia and iron deficiency in compensated and decompensated cirrhosis: prevalence and impact on clinical outcomes.
    J Gastroenterol Hepatol. 2020 Jan 23. doi: 10.1111/jgh.14988.
    PubMed     Abstract available

  32. KOGISO T, Sagawa T, Kodama K, Taniai M, et al
    Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population.
    J Gastroenterol Hepatol. 2020 Jan 23. doi: 10.1111/jgh.14989.
    PubMed     Abstract available

  33. TOYODA H, Atsukawa M, Watanabe T, Nakamuta M, et al
    Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic HCV infection in a real-word setting: a large, multicenter study from Japan.
    J Gastroenterol Hepatol. 2020 Jan 16. doi: 10.1111/jgh.14982.
    PubMed     Abstract available

    December 2019
  34. ATSUKAWA M, Tsubota A, Takaguchi K, Toyoda H, et al
    Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema.
    J Gastroenterol Hepatol. 2019 Dec 27. doi: 10.1111/jgh.14965.
    PubMed     Abstract available

  35. LI Y, Zhang Y, Chen T, Huang Y, et al
    Aldosterone induces activation of primary mice hepatic stellate cell and liver fibrosis via NLRP3 inflammasome.
    J Gastroenterol Hepatol. 2019 Dec 20. doi: 10.1111/jgh.14961.
    PubMed     Abstract available

  36. SOHN W, Kim JH, Cho JY
    Effect of acute kidney injury on long-term outcomes of spontaneous bacterial peritonitis in cirrhotic patients using the International Club of Ascites-acute kidney injury criteria.
    J Gastroenterol Hepatol. 2019 Dec 9. doi: 10.1111/jgh.14871.
    PubMed     Abstract available

    November 2019
  37. JOSHITA S, Yamashita Y, Sugiura A, Uehara T, et al
    Clinical utility of FibroScan as a non-invasive diagnostic test for primary biliary cholangitis.
    J Gastroenterol Hepatol. 2019 Nov 14. doi: 10.1111/jgh.14929.
    PubMed     Abstract available

  38. VARELAS LJ, Klinge MJ, Malik SM, Borhani AA, et al
    J Gastroenterol Hepatol. 2019 Nov 6. doi: 10.1111/jgh.14920.
    PubMed     Abstract available

  39. FRENCH J, van der Mei I, Simpson S Jr, Ng J, et al
    Increasing Prevalence of Primary Biliary Cholangitis in Victoria, Australia.
    J Gastroenterol Hepatol. 2019 Nov 6. doi: 10.1111/jgh.14924.
    PubMed     Abstract available

  40. WU CK, Yang SC, Liang CM, Li YC, et al
    The role of antibiotics in upper gastrointestinal bleeding among cirrhotic patients without major complications after endoscopic hemostasis.
    J Gastroenterol Hepatol. 2019 Nov 1. doi: 10.1111/jgh.14873.
    PubMed     Abstract available

  41. TAKANO K, Saeki C, Oikawa T, Hidaka A, et al
    IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate.
    J Gastroenterol Hepatol. 2019 Nov 1. doi: 10.1111/jgh.14900.
    PubMed     Abstract available

    October 2019
  42. TOBARI M, Hashimoto E, Taniai M, Kodama K, et al
    The characteristics and risk factors of hepatocellular carcinoma in non-alcoholic fatty liver disease without cirrhosis.
    J Gastroenterol Hepatol. 2019 Oct 9. doi: 10.1111/jgh.14867.
    PubMed     Abstract available

    September 2019
  43. ZHAO S, Xu W, Xie YX, Chen WW, et al
    CXCR5(+) CD4(+) T cell subsets and their relationship to immune dysfunction in chronic hepatitis B associated liver cirrhosis.
    J Gastroenterol Hepatol. 2019 Sep 13. doi: 10.1111/jgh.14866.
    PubMed     Abstract available

  44. HEUCKE N, Wuensch T, Mohr J, Kaffarnik M, et al
    Non-invasive structure-function assessment of the liver by 2D time-harmonic elastography and the dynamic Liver MAximum capacity (LiMAx) test.
    J Gastroenterol Hepatol. 2019;34:1611-1619.
    PubMed     Abstract available

  45. KANG MK, Park JG, Lee HJ, Kim MC, et al
    Association of low skeletal muscle mass with advanced liver fibrosis in patients with non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2019;34:1633-1640.
    PubMed     Abstract available

    August 2019
  46. SOBOTKA LA, Risaliti C, Hinton A, Michaels A, et al
    Management of Hepatic Hydrothorax and Effect on Length of Stay, Mortality, Cost, and 30-Day Hospital Readmission.
    J Gastroenterol Hepatol. 2019 Aug 23. doi: 10.1111/jgh.14842.
    PubMed     Abstract available

  47. SAWADA Y, Kawaratani H, Kubo T, Fujinaga Y, et al
    Effect of furosemide on muscle cramps in patients with liver cirrhosis.
    J Gastroenterol Hepatol. 2019 Aug 5. doi: 10.1111/jgh.14820.
    PubMed     Abstract available

  48. WONG GL, Wong VW
    Non-alcoholic fatty liver disease in Asia: How is it different from the West?
    J Gastroenterol Hepatol. 2019;34:1267-1268.

  49. FUJII H, Imajo K, Yoneda M, Nakahara T, et al
    HOMA-IR: An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2019;34:1390-1395.
    PubMed     Abstract available

  50. LAI LL, Wan Yusoff WNI, Vethakkan SR, Nik Mustapha NR, et al
    Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
    J Gastroenterol Hepatol. 2019;34:1396-1403.
    PubMed     Abstract available

  51. TOMENO W, Imajo K, Kuwada Y, Ogawa Y, et al
    Distribution of liver stiffness in non-alcoholic fatty liver disease with higher fibrosis-4 index than low cut-off index.
    J Gastroenterol Hepatol. 2019;34:1411-1416.
    PubMed     Abstract available

    July 2019
  52. LEAO GS, Neto GJ, de Freitas Jotz R, Alves de Mattos AA, et al
    Albumin for cirrhotic patients with extraperitoneal infections: a meta-analysis.
    J Gastroenterol Hepatol. 2019 Jul 28. doi: 10.1111/jgh.14791.
    PubMed     Abstract available

  53. GUPTA T, Lochan D, Verma N, Rathi S, et al
    Presence of Multidrug-resistant Infections at Admission Predict 28-day mortality in Acute Decompensation of Cirrhosis.
    J Gastroenterol Hepatol. 2019 Jul 23. doi: 10.1111/jgh.14788.
    PubMed     Abstract available

  54. PATEL K, Mumtaz K, Li F, Luthra A, et al
    Index Admission Cholecystectomy for Acute Biliary Pancreatitis Favorably Impacts Outcomes of Hospitalization in Cirrhosis.
    J Gastroenterol Hepatol. 2019 Jul 1. doi: 10.1111/jgh.14775.
    PubMed     Abstract available

  55. IWAMOTO T, Maeda M, Saeki I, Hidaka I, et al
    Analysis of tolvaptan non-responders and outcomes of tolvaptan treatment of ascites.
    J Gastroenterol Hepatol. 2019;34:1231-1235.
    PubMed     Abstract available

  56. SAKAMOTO N, Suda G, Morikawa K, Ogawa K, et al
    Nutrition is often ignored in management of chronic liver diseases.
    J Gastroenterol Hepatol. 2019;34:1127-1128.

    June 2019
  57. REKIK S, Allaire M, Mumana A, Guyot E, et al
    Transient elastography predicts survival after radiofrequency ablation of hepatocellular carcinoma developing on cirrhosis.
    J Gastroenterol Hepatol. 2019 Jun 24. doi: 10.1111/jgh.14763.
    PubMed     Abstract available

  58. LIU J, Shi Q, Xiao SP, Zhou C, et al
    Using transjugular intrahepatic portosystemic shunt as the first-line therapy in secondary prophylaxis of variceal hemorrhage.
    J Gastroenterol Hepatol. 2019 Jun 20. doi: 10.1111/jgh.14761.
    PubMed     Abstract available

    May 2019
  59. SEMMLER G, Simbrunner B, Scheiner B, Schwabl P, et al
    Impact of farnesoid X receptor SNPs on hepatic decompensation and mortality in cirrhotic patients with portal hypertension.
    J Gastroenterol Hepatol. 2019 May 6. doi: 10.1111/jgh.14700.
    PubMed     Abstract available

    April 2019
  60. WATSON H, Guevara M, Vilstrup H, Gines P, et al
    Improvement of hyponatremia in cirrhosis is associated with improved complex information processing.
    J Gastroenterol Hepatol. 2019 Apr 9. doi: 10.1111/jgh.14683.
    PubMed     Abstract available

  61. LIU CH, Shih YL, Yang SS, Lin CL, et al
    Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East-Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis.
    J Gastroenterol Hepatol. 2019 Apr 1. doi: 10.1111/jgh.14672.
    PubMed     Abstract available

  62. DONG XQ, Wu Z, Li J, Wang GQ, et al
    Declining in liver stiffness cannot indicate fibrosis regression in patients with chronic hepatitis B: A 78-week prospective study.
    J Gastroenterol Hepatol. 2019;34:755-763.
    PubMed     Abstract available

    March 2019
  63. CHEN CJ, Wang LC, Kuo HT, Fang YC, et al
    Late-evening snacking improves liver functions in patients with liver cirrhosis: A meta-analysis of randomized controlled trials.
    J Gastroenterol Hepatol. 2019 Mar 18. doi: 10.1111/jgh.14665.
    PubMed     Abstract available

  64. FOUAD TR, Abdelsameea E, Abdel-Razek W, Attia A, et al
    Upper gastrointestinal bleeding in Egyptian patients with cirrhosis: Post-therapeutic outcome and prognostic indicators.
    J Gastroenterol Hepatol. 2019 Mar 14. doi: 10.1111/jgh.14659.
    PubMed     Abstract available

  65. ZENG X, Li XX, Shi PM, Zhang YY, et al
    Utility of the EncephalApp Stroop Test for Covert Hepatic Encephalopathy Screening in Chinese Cirrhotic Patients.
    J Gastroenterol Hepatol. 2019 Mar 12. doi: 10.1111/jgh.14656.
    PubMed     Abstract available

  66. YAMATO M, Sakai Y, Mochida H, Kawaguchi K, et al
    Adipose tissue-derived stem cells prevent fibrosis in murine steatohepatitis by suppressing IL-17-mediated inflammation.
    J Gastroenterol Hepatol. 2019 Mar 3. doi: 10.1111/jgh.14647.
    PubMed     Abstract available

  67. KOBAYAKAWA M, Ohnishi S, Suzuki H
    Recent development of balloon-occluded retrograde transvenous obliteration.
    J Gastroenterol Hepatol. 2019;34:495-500.
    PubMed     Abstract available

  68. KUK N, Hodge A, Sun Y, Correia J, et al
    Human amnion epithelial cells and their soluble factors reduce liver fibrosis in a murine non-alcoholic steatohepatitis.
    J Gastroenterol Hepatol. 2019 Mar 1. doi: 10.1111/jgh.14643.
    PubMed     Abstract available

    February 2019
  69. HANAI T, Shiraki M, Watanabe S, Imai K, et al
    Prognostic significance of minimal hepatic encephalopathy in patients with liver cirrhosis in Japan: a propensity score-matching analysis.
    J Gastroenterol Hepatol. 2019 Feb 18. doi: 10.1111/jgh.14635.
    PubMed     Abstract available

  70. LIU CJ, Tseng TC, Yang WT, Su TH, et al
    Profile and value of FIB-4 in patients with dual chronic hepatitis C and B.
    J Gastroenterol Hepatol. 2019;34:410-417.
    PubMed     Abstract available

    January 2019
  71. KODAMA K, Kawaguchi T, Hyogo H, Nakajima T, et al
    Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis.
    J Gastroenterol Hepatol. 2019 Jan 22. doi: 10.1111/jgh.14608.
    PubMed     Abstract available

  72. HOWELL J, Pedrana A, Cowie BC, Doyle J, et al
    Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030.
    J Gastroenterol Hepatol. 2019;34:40-48.
    PubMed     Abstract available

  73. ITO T, Ishigami M, Ishizu Y, Kuzuya T, et al
    Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients.
    J Gastroenterol Hepatol. 2019;34:207-214.
    PubMed     Abstract available

  74. ISHIKAWA T, Sasaki R, Nishimura T, Matsuda T, et al
    Liver stiffness measured by transient elastography as predictor of prognoses following portosystemic shunt occlusion.
    J Gastroenterol Hepatol. 2019;34:215-223.
    PubMed     Abstract available

  75. CHOW JC, Wong GL, Chan AW, Shu SS, et al
    Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness.
    J Gastroenterol Hepatol. 2019;34:241-248.
    PubMed     Abstract available

    December 2018
  76. TOBARI M, Hashimoto E, Taniai M, Ikarashi Y, et al
    Characteristics of nonalcoholic steatohepatitis among lean patients in Japan: not uncommon and not always benign.
    J Gastroenterol Hepatol. 2018 Dec 27. doi: 10.1111/jgh.14585.
    PubMed     Abstract available

    November 2018
  77. BOSSEN L, Gines P, Vilstrup H, Watson H, et al
    Serum sodium as a risk factor for hepatic encephalopathy in patients with cirrhosis and ascites.
    J Gastroenterol Hepatol. 2018 Nov 30. doi: 10.1111/jgh.14558.
    PubMed     Abstract available

  78. SUN Y, Lan X, Shao C, Wang T, et al
    Clinical Features of Idiopathic Portal Hypertension in China: A Retrospective Study of 338 Patients and Literature Review.
    J Gastroenterol Hepatol. 2018 Nov 21. doi: 10.1111/jgh.14552.
    PubMed     Abstract available

  79. DASHPUTRE AA, Nemecek BD, Kamal KM, Covvey JR, et al
    The relationship between a cirrhosis-specific comorbidity scoring system and healthcare utilization patterns.
    J Gastroenterol Hepatol. 2018 Nov 5. doi: 10.1111/jgh.14531.
    PubMed     Abstract available

  80. BATSAIKHAN B, Huang CI, Yeh ML, Huang CF, et al
    Association between cryoglobulinemia and liver fibrosis in chronic hepatitis C patients.
    J Gastroenterol Hepatol. 2018;33:1897-1903.
    PubMed     Abstract available

    October 2018
  81. CHEN S, Duan W, Li M, Li S, et al
    Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: a single center follow-up study from China.
    J Gastroenterol Hepatol. 2018 Oct 26. doi: 10.1111/jgh.14521.
    PubMed     Abstract available

  82. COOL J, Rosenblatt R, Kumar S, Lucero C, et al
    J Gastroenterol Hepatol. 2018 Oct 11. doi: 10.1111/jgh.14501.
    PubMed     Abstract available

    September 2018
  83. MOLLER S, La Cour Sibbesen E, Madsen JL, Bendtsen F, et al
    The indocyanine green retention test in cirrhosis and portal hypertension. Accuracy and relation to severity of disease.
    J Gastroenterol Hepatol. 2018 Sep 17. doi: 10.1111/jgh.14470.
    PubMed     Abstract available

    August 2018
  84. WU SC, Chen WT, Muo CH, Hsu CY, et al
    A comparative study of subsequent liver cirrhosis risk in non- helicobacter pylori infected peptic ulcer patients with and without vagotomy: an Asian population cohort study.
    J Gastroenterol Hepatol. 2018 Aug 12. doi: 10.1111/jgh.14440.
    PubMed     Abstract available

  85. YAMADA N, Katano T, Hirata Y, Okada N, et al
    Serum Mac-2 Binding Protein Glycosylation isomer predicts the activation of hepatic stellate cells after liver transplantation.
    J Gastroenterol Hepatol. 2018 Aug 12. doi: 10.1111/jgh.14438.
    PubMed     Abstract available

  86. YEH CS, Hsu CW, Liang KH, Chen YC, et al
    Development of a fibrosis index including hepatitis B virus basal core promoter A1762T mutation for pretherapeutic evaluation.
    J Gastroenterol Hepatol. 2018;33:1530-1537.
    PubMed     Abstract available

    July 2018
  87. KIM TH, Lee HA, Seo YS, Lee YR, et al
    Assessment and prediction of acute kidney injury in patients with decompensated cirrhosis with serum cystatin C and urine N-acetyl-beta-D-glucosaminidase.
    J Gastroenterol Hepatol. 2018 Jul 30. doi: 10.1111/jgh.14387.
    PubMed     Abstract available

  88. WANG HW, Lai HC, Hu TH, Su WP, et al
    Modified FIB-4 index stratifies hepatocellular carcinoma risk in chronic hepatitis B patients on entecavir therapy.
    J Gastroenterol Hepatol. 2018 Jul 3. doi: 10.1111/jgh.14372.
    PubMed     Abstract available

  89. CHOE WH, Kim H, Lee SY, Choi YM, et al
    Three types of preS1 start codon deletion variants in the natural course of chronic hepatitis B infection.
    J Gastroenterol Hepatol. 2018;33:1370-1378.
    PubMed     Abstract available

  90. ADINOLFI LE, Nevola R, Guerrera B, D'Alterio G, et al
    Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients.
    J Gastroenterol Hepatol. 2018;33:1379-1382.
    PubMed     Abstract available

    June 2018
  91. LEE DH, Ahn JH, Chung JW, Kim YJ, et al
    Varices on CT is Surrogate of Clinically Significant Portal Hypertension and can Predict Survival in Compensated Cirrhosis Patients.
    J Gastroenterol Hepatol. 2018 Jun 14. doi: 10.1111/jgh.14319.
    PubMed     Abstract available

  92. LIU T, Xu L, Wang C, Chen K, et al
    Shikonin alleviates hepatic fibrosis and autophagy via inhibition of TGF-beta1/Smads pathway.
    J Gastroenterol Hepatol. 2018 Jun 4. doi: 10.1111/jgh.14299.
    PubMed     Abstract available

  93. DONG XQ, Li J, Liu H, Wang YW, et al
    Hepatobiliary and Pancreatic: A rare cause of decompensated liver cirrhosis.
    J Gastroenterol Hepatol. 2018 Jun 3. doi: 10.1111/jgh.14273.

  94. MAHADY SE, Adams LA
    Burden of non-alcoholic fatty liver disease in Australia.
    J Gastroenterol Hepatol. 2018;33 Suppl 1:1-11.
    PubMed     Abstract available

    May 2018
  95. UOJIMA H, Hidaka H, Tanaka Y, Inoue T, et al
    Wisteria floribunda agglutinin-positive human Mac-2 binding protein in decompensated cirrhosis.
    J Gastroenterol Hepatol. 2018 May 8. doi: 10.1111/jgh.14277.
    PubMed     Abstract available

  96. WONG GL
    Non-invasive assessments for liver fibrosis: The crystal ball we long for.
    J Gastroenterol Hepatol. 2018;33:1009-1015.
    PubMed     Abstract available

  97. HUANG CF, Yeh ML, Huang CI, Lin ZY, et al
    Interference of hepatitis B virus dual infection in platelet count recovery in chronic hepatitis C patients with curative antiviral therapy.
    J Gastroenterol Hepatol. 2018;33:1108-1114.
    PubMed     Abstract available

    April 2018
  98. HABIB S, Patel N, Yarlagadda S, Hsu CH, et al
    Safety and efficacy of antibiotics among acutely decompensated cirrhosis patients.
    J Gastroenterol Hepatol. 2018 Apr 26. doi: 10.1111/jgh.14267.
    PubMed     Abstract available

    March 2018
  99. TANDON P, Bishay K, Fisher S, Yelle D, et al
    Comparison of Clinical Outcomes Between Variceal and Non-Variceal Gastrointestinal Bleeding in Patients with Cirrhosis.
    J Gastroenterol Hepatol. 2018 Mar 30. doi: 10.1111/jgh.14147.
    PubMed     Abstract available

  100. PAPALUCA T, Gow P
    Terlipressin: Current and emerging indications in chronic liver disease.
    J Gastroenterol Hepatol. 2018;33:591-598.
    PubMed     Abstract available

    February 2018
  101. KIM TH, Ku DH, Um SH, Lee HA, et al
    How can we improve the performance of MELDNa score in patients with HBV-related decompensated liver cirrhosis commencing antiviral treatment?
    J Gastroenterol Hepatol. 2018 Feb 20. doi: 10.1111/jgh.14128.
    PubMed     Abstract available

  102. WIGG AJ, Chin JK, Muller KR, Ramachandran J, et al
    A Chronic Disease Management Model for Cirrhosis is Cost-Effective: Analysis of a Randomized Controlled Trial.
    J Gastroenterol Hepatol. 2018 Feb 20. doi: 10.1111/jgh.14127.
    PubMed     Abstract available

  103. DOI H, Hayashi E, Arai J, Tojo M, et al
    Advanced cirrhosis drives enhanced B-cell differentiation resulting in hyperglobulinemia.
    J Gastroenterol Hepatol. 2018 Feb 10. doi: 10.1111/jgh.14123.
    PubMed     Abstract available

  104. PARENTE DB, Oliveira Neto JA, Brasil PEAA, Paiva FF, et al
    Preperitoneal fat as a non-invasive marker of increased risk of severe non-alcoholic fatty liver disease in patients with type 2 diabetes.
    J Gastroenterol Hepatol. 2018;33:511-517.
    PubMed     Abstract available

    January 2018
  105. KAO JH, Yu ML, Chen CY, Peng CY, et al
    Twelve-week Ravidasvir plus ritonavir-boosted Danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study.
    J Gastroenterol Hepatol. 2018 Jan 18. doi: 10.1111/jgh.14096.
    PubMed     Abstract available

  106. KIM NH, Lee T, Cho YK, Kim BI, et al
    Impact of clinically evident portal hypertension on clinical outcome of patients with hepatocellular carcinoma treated by transarterial chemoembolization.
    J Gastroenterol Hepatol. 2018 Jan 3. doi: 10.1111/jgh.14083.
    PubMed     Abstract available

  107. FANG X, Liu LW, Dong J, Zhang J, et al
    A study about immunomodulatory effect and efficacy and prognosis of hUCMSCs in patients with CHB-induced decompensated liver cirrhosis.
    J Gastroenterol Hepatol. 2018 Jan 2. doi: 10.1111/jgh.14081.
    PubMed     Abstract available

  108. CHEN YP, Hu XM, Liang XE, Huang LW, et al
    Stepwise application of fibrosis index based on four factors, red cell distribution width-platelet ratio, and aspartate aminotransferase-platelet ratio for compensated hepatitis B fibrosis detection.
    J Gastroenterol Hepatol. 2018;33:256-263.
    PubMed     Abstract available

    December 2017
  109. ATSUKAWA M, Tsubota A, Kato K, Abe H, et al
    Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema.
    J Gastroenterol Hepatol. 2017 Dec 7. doi: 10.1111/jgh.14047.
    PubMed     Abstract available

  110. ZHOU LY, Ma YJ, Tian F
    Hepatobiliary and Pancreatic: Management of bleeding colonic varices in liver disease.
    J Gastroenterol Hepatol. 2017;32:1913.

    November 2017
  111. ISHIGAMI M, Hayashi K, Honda T, Kuzuya T, et al
    Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by hepatitis C virus genotype 1b infection: Real-world data.
    J Gastroenterol Hepatol. 2017;32:1879-1886.
    PubMed     Abstract available

    October 2017
  112. OTANI I, Oka S, Tanaka S, Tsuboi A, et al
    Clinical significance of small-bowel villous edema in patients with liver cirrhosis-a capsule endoscopy study.
    J Gastroenterol Hepatol. 2017 Oct 10. doi: 10.1111/jgh.14016.
    PubMed     Abstract available

  113. CHOE EY, Lee YH, Choi YJ, Huh BW, et al
    Waist-to-calf ratio is an independent predictor of hepatic steatosis and fibrosis patients with type 2 diabetes.
    J Gastroenterol Hepatol. 2017 Oct 8. doi: 10.1111/jgh.14011.
    PubMed     Abstract available

  114. DING F, Li Q, Duan X, Ye J, et al
    Hepatobiliary and Pancreatic: Ruptured aneurysm of intra-hepatic portal vein causing obstructive jaundice.
    J Gastroenterol Hepatol. 2017;32:1666.

    September 2017
  115. TADA T, Kumada T, Toyoda H, Kobayashi N, et al
    Hepatitis B virus core-related antigen levels predict progression to liver cirrhosis in hepatitis B carriers.
    J Gastroenterol Hepatol. 2017 Sep 15. doi: 10.1111/jgh.13989.
    PubMed     Abstract available

  116. SEO YS, Park SY, Kim MY, Kim SG, et al
    Serum cystatin C level is an excellent predictor of mortality in patients with cirrhotic ascites.
    J Gastroenterol Hepatol. 2017 Sep 14. doi: 10.1111/jgh.13983.
    PubMed     Abstract available

  117. ZHANG B, Zhang CG, Ji LH, Zhao G, et al
    Estrogen receptor beta selective agonist ameliorates liver cirrhosis in rats by inhibiting the activation and proliferation of hepatic stellate cells.
    J Gastroenterol Hepatol. 2017 Sep 7. doi: 10.1111/jgh.13976.
    PubMed     Abstract available

    August 2017
  118. CHIRAPONGSATHORN S, Bunraksa W, Chaiprasert A, Punpanich D, et al
    Adding C-reactive protein and procalcitonin to the MELD score improves mortality prediction in patients with complications of cirrhosis.
    J Gastroenterol Hepatol. 2017 Aug 25. doi: 10.1111/jgh.13928.
    PubMed     Abstract available

  119. AMPUERO J, Montoliu C, Simon-Talero M, Aguilera V, et al
    Minimal hepatic encephalopathy identifies patients at risk of faster cirrhosis progression.
    J Gastroenterol Hepatol. 2017 Aug 2. doi: 10.1111/jgh.13917.
    PubMed     Abstract available

    July 2017
  120. DE SANTIS A, Nardelli S, Bassanelli C, Lupo M, et al
    The modification of splenic stiffness on acoustic radiation force impulse parallels the variation of portal pressure induced by transjugular intrahepatic portosystemic shunt.
    J Gastroenterol Hepatol. 2017 Jul 28. doi: 10.1111/jgh.13907.
    PubMed     Abstract available

  121. ELNEGOULY M, Umgelter K, Safi W, Hapfelmeier A, et al
    Elevated Cardiac Troponin T in Cirrhotic Patients with Emergency Care Admissions is Associated with Mortality.
    J Gastroenterol Hepatol. 2017 Jul 20. doi: 10.1111/jgh.13902.
    PubMed     Abstract available

  122. KIMER N, Pedersen JS, Tavenier J, Christensen JE, et al
    Rifaximin has minor effects on bacterial composition, inflammation and bacterial translocation in cirrhosis; A randomized trial.
    J Gastroenterol Hepatol. 2017 Jul 3. doi: 10.1111/jgh.13852.
    PubMed     Abstract available

    June 2017
  123. KIM BS, Seo YS, Kim YS, Lee CH, et al
    Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis.
    J Gastroenterol Hepatol. 2017 Jun 30. doi: 10.1111/jgh.13854.
    PubMed     Abstract available

  124. FUJITA K, Niki T, Nomura T, Oura K, et al
    Serum galectin-9 levels are correlated to liver fibrosis regardless of chronic inflammation or hepatocellular carcinoma complications.
    J Gastroenterol Hepatol. 2017 Jun 15. doi: 10.1111/jgh.13851.
    PubMed     Abstract available

  125. BERTRAIS S, Boursier J, Ducancelle A, Oberti F, et al
    Prognostic durability of liver fibrosis tests and improvement in predictive performance for mortality by combining tests.
    J Gastroenterol Hepatol. 2017;32:1240-1249.
    PubMed     Abstract available

  126. CHAN HL, Tsang OT, Hui YT, Fung J, et al
    Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong.
    J Gastroenterol Hepatol. 2017;32:1230-1233.
    PubMed     Abstract available

    May 2017
  127. LIU CH, Liu CJ, Hong CM, Su TH, et al
    A noninvasive diagnosis of hepatic fibrosis by BioFibroScore(R) in chronic hepatitis C patients.
    J Gastroenterol Hepatol. 2017 May 26. doi: 10.1111/jgh.13834.
    PubMed     Abstract available

  128. KIM JH, Lim KS, Min YW, Lee H, et al
    Proton pump inhibitors do not increase the risk for recurrent spontaneous bacterial peritonitis in patients with cirrhosis.
    J Gastroenterol Hepatol. 2017;32:1064-1070.
    PubMed     Abstract available

  129. JUN DW, Kim SG, Park SH, Jin SY, et al
    External validation of the non-alcoholic fatty liver disease fibrosis score for assessing advanced fibrosis in Korean patients.
    J Gastroenterol Hepatol. 2017;32:1094-1099.
    PubMed     Abstract available

  130. PARKER R, Hodson J, Rowe IAC
    Systematic review: Current evidence in non-alcoholic fatty liver disease lacks relevance to patients with advanced fibrosis.
    J Gastroenterol Hepatol. 2017;32:950-956.
    PubMed     Abstract available

    April 2017
  131. ITO K, Murotani K, Nakade Y, Inoue T, et al
    Serum WFA+ -M2BP levels predict liver fibrosis, development of hepatocellular carcinoma, and overall survival: A meta-analysis.
    J Gastroenterol Hepatol. 2017 Apr 12. doi: 10.1111/jgh.13802.
    PubMed     Abstract available

    March 2017
  132. HSIEH YC, Lee KC, Chen PH, Su CW, et al
    Acute kidney injury predicts mortality in cirrhotic patients with gastric variceal bleeding.
    J Gastroenterol Hepatol. 2017 Mar 8. doi: 10.1111/jgh.13777.
    PubMed     Abstract available

  133. TADA T, Kumada T, Toyoda H, Kiriyama S, et al
    Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis.
    J Gastroenterol Hepatol. 2017;32:687-694.
    PubMed     Abstract available

  134. XU Q, Sheng L, Bao H, Chen X, et al
    Evaluation of transient elastography in assessing liver fibrosis in patients with autoimmune hepatitis.
    J Gastroenterol Hepatol. 2017;32:639-644.
    PubMed     Abstract available

  135. LIU Z, Wei X, Chen T, Huang C, et al
    Characterization of fibrosis changes in chronic hepatitis C patients after virological cure: A systematic review with meta-analysis.
    J Gastroenterol Hepatol. 2017;32:548-557.
    PubMed     Abstract available

    February 2017
  136. JEON SR, Byeon JS, Jang HJ, Park SJ, et al
    Clinical outcome after enteroscopy for small bowel angioectasia bleeding: A Korean Associateion for the Study of Intestinal Disease (KASID) multiceter study.
    J Gastroenterol Hepatol. 2017;32:388-394.
    PubMed     Abstract available

  137. SOOD A, Khurana MS, Mahajan R, Midha V, et al
    Prevalence and clinical significance of IgA anti-tissue transglutaminase antibodies in patients with chronic liver disease.
    J Gastroenterol Hepatol. 2017;32:446-450.
    PubMed     Abstract available

    January 2017
  138. SEKI A, Ikeda F, Miyatake H, Takaguchi K, et al
    Risk of secondary osteoporosis due to lobular cholestasis in non-cirrhotic primary biliary cholangitis.
    J Gastroenterol Hepatol. 2017 Jan 23. doi: 10.1111/jgh.13746.
    PubMed     Abstract available

  139. LEE SJ, Kim SU, Kim MD, Kim YH, et al
    Comparison of treatment outcomes between balloon-occluded retrograde transvenous obliteration and transjugular intrahepatic portosystemic shunt for gastric variceal bleeding hemostasis.
    J Gastroenterol Hepatol. 2017 Jan 13. doi: 10.1111/jgh.13729.
    PubMed     Abstract available

  140. WANG Y, Huang W, Li R, Yun Z, et al
    Systematic Quantitation of Histologic Patterns Shows Accuracy in Reflecting Cirrhotic Remodeling.
    J Gastroenterol Hepatol. 2017 Jan 9. doi: 10.1111/jgh.13722.
    PubMed     Abstract available

  141. REY S, Quintavalle C, Burmeister K, Calabrese D, et al
    J Gastroenterol Hepatol. 2017 Jan 3. doi: 10.1111/jgh.13717.
    PubMed     Abstract available

    December 2016
  142. BEKKI Y, Yoshizumi T, Shimoda S, Itoh S, et al
    Hepatic stellate cells secrete WFA+ -M2BP; its role in biological interactions with Kupffer cells.
    J Gastroenterol Hepatol. 2016 Dec 22. doi: 10.1111/jgh.13708.
    PubMed     Abstract available

  143. CHETCUTI ZAMMIT S, Chircop A, Cortis K, Pullicino E, et al
    Hepatobiliary and Pancreatic: Congenital intrahepatic portosystemic venous shunting: A great mimicker of liver cirrhosis.
    J Gastroenterol Hepatol. 2016;31:1917.

    November 2016
  144. LEE YR, Park SY, Kim SU, Jang SY, et al
    Using transient elastography to predict hepatocellular carcinoma recurrence after radiofrequency ablation.
    J Gastroenterol Hepatol. 2016 Nov 10. doi: 10.1111/jgh.13644.
    PubMed     Abstract available

  145. BUSK TM, Moller S, Pedersen EB, Gerbes A, et al
    Aquaporin-2 Excretion in Hospitalized Patients with Cirrhosis: Relation to Development of Renal Insufficiency and Mortality.
    J Gastroenterol Hepatol. 2016 Nov 7. doi: 10.1111/jgh.13641.
    PubMed     Abstract available

    October 2016
  146. AHN JM, Kim CH, Um SH, Kim KM, et al
    A validation Study Associating Glutaminase Promoter Variations with Hepatic Encephalopathy in East Asian Populations.
    J Gastroenterol Hepatol. 2016 Oct 17. doi: 10.1111/jgh.13618.
    PubMed     Abstract available

    July 2016
  147. PARK TY, Lee SK, Nam K, Oh D, et al
    Spontaneous hemobilia after liver transplantation: frequency, risk factors, and outcome of endoscopic management.
    J Gastroenterol Hepatol. 2016 Jul 23. doi: 10.1111/jgh.13497.
    PubMed     Abstract available

    April 2016
  148. TARDELLI M, Moreno-Viedma V, Zeyda M, Itariu BK, et al
    Adiponectin regulates aquaglyceroporin expression in hepatic stellate cells altering their functional state.
    J Gastroenterol Hepatol. 2016 Apr 15. doi: 10.1111/jgh.13415.
    PubMed     Abstract available

    February 2016
  149. PELUCCHI S, Galimberti S, Greni F, Rametta R, et al
    Proprotein convertase 7 rs236918 is associated with liver fibrosis in Italian patients with HFE-related Hemochromatosis.
    J Gastroenterol Hepatol. 2016 Feb 11. doi: 10.1111/jgh.13315.
    PubMed     Abstract available

    December 2015
  150. EATON JE, Dzyubak B, Venkatesh SK, Smyrk TC, et al
    Performance of magnetic resonance elastography in primary sclerosing cholangitis.
    J Gastroenterol Hepatol. 2015 Dec 21. doi: 10.1111/jgh.13263.
    PubMed     Abstract available

  151. VAN DER MEER AJ, Maan R, Veldt BJ, Feld JJ, et al
    Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis.
    J Gastroenterol Hepatol. 2015 Dec 8. doi: 10.1111/jgh.13252.
    PubMed     Abstract available

    November 2015
  152. GASSIEP I, Clark PJ, McManus DP, Looke DL, et al
    Hepatobiliary and Pancreatic: Acute hepatitis in the setting of chronic schistosoma mansoni infection and post- praziquantel therapy.
    J Gastroenterol Hepatol. 2015 Nov 24. doi: 10.1111/jgh.13239.

  153. NAGAOKI Y, Aikata H, Nakano N, Shinohara F, et al
    Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study.
    J Gastroenterol Hepatol. 2015 Nov 19. doi: 10.1111/jgh.13236.
    PubMed     Abstract available

  154. KIM Y, Lee EJ, Jang HK, Kim CH, et al
    Statin pretreatment inhibits the LPS-induced EMT via the downregulation of TLR4 and NF-kappaB in human biliary epithelial cells.
    J Gastroenterol Hepatol. 2015 Nov 17. doi: 10.1111/jgh.13230.
    PubMed     Abstract available

    October 2015
  155. BALDUCCI G, Sterpetti AV, Ventura M
    A short history of portal hypertension and of its management.
    J Gastroenterol Hepatol. 2015 Oct 29. doi: 10.1111/jgh.13200.
    PubMed     Abstract available

    August 2015
  156. MORGAN ML, Sigala B, Soeda J, Cordero P, et al
    Acetylcholine induces fibrogenic effects via M2/M3 ACh receptors in NASH and in primary human hepatic stellate cells.
    J Gastroenterol Hepatol. 2015 Aug 13. doi: 10.1111/jgh.13085.
    PubMed     Abstract available

  157. TU T, Calabro SR, Lee A, Maczurek AE, et al
    Hepatocytes in liver injury: victim, bystander, or accomplice in progressive fibrosis?
    J Gastroenterol Hepatol. 2015 Aug 4. doi: 10.1111/jgh.13065.
    PubMed     Abstract available

    July 2015
  158. ZHANG CX, Xu JM, Li JB, Kong DR, et al
    Predict esophageal varices via routine trans-abdominal ultrasound: A design of classification analysis model.
    J Gastroenterol Hepatol. 2015 Jul 21. doi: 10.1111/jgh.13045.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.